{"database": "press", "table": "releases", "rows": [["https://krishnamoorthi.house.gov/media/press-releases/krishnamoorthi-demands-answers-fda-move-rewrite-vaping-approval-rules-blasts", "Krishnamoorthi Demands Answers on FDA Move to Rewrite Vaping Approval Rules, Blasts Weakening of Scientific Standards", "2026-10-06", "2026", "2026-10", "Democrat", "House", "IL", "Raja Krishnamoorthi", "K000391", "krishnamoorthi.house.gov", "krishnamoorthi", "https://krishnamoorthi.house.gov/media/press-releases", "scraper", "WASHINGTON \u2014 Congressman Raja Krishnamoorthi (D-IL), co-chair of the bipartisan Congressional Caucus to End Youth Vaping, today demanded answers from Food and Drug Administration Acting Commissioner Kyle Diamantas over FDA\u2019s September 28 announcement that it is considering new rulemaking to replace the 2021 regulations governing approval of new tobacco products, pressing the agency over whether the move could weaken the scientific standards manufacturers must meet.\n\nKrishnamoorthi is also demanding to know whether FDA discussed potential changes with tobacco manufacturers, industry associations, or parties challenging the current rules before announcing its review, and is seeking communications between agency officials and Altria, Reynolds American, their subsidiaries and representatives, and other parties challenging the framework.\n\nFDA announced its review less than four weeks after Altria subsidiaries NJOY and Helix Innovations sued the agency over the current Premarket Tobacco Product Application framework. FDA itself cited recent litigation challenging the framework, along with the widespread illicit tobacco market, in explaining its decision to consider replacing the rule.\n\n\u201cThe widespread sale of illegal products is an enforcement problem,\u201d Krishnamoorthi wrote. \u201cIt should not become a justification for lowering the evidentiary requirements manufacturers must satisfy before FDA authorizes their products.\u201d\n\nKrishnamoorthi also raised concerns about the review in light of FDA\u2019s recent authorization of flavored e-cigarette products. In May, the agency authorized Glas products in mango and blueberry flavors despite FDA data indicating that fruit-flavored e-cigarettes are the most popular flavor among youth. The letter notes that the FDA Center for Tobacco Products did not require the manufacturer to demonstrate that the flavors provided an added benefit to adults attempting to transition from combustible products, and that former FDA Commissioner Marty Makary reportedly resigned in part amid political interference surrounding the authorization.\n\nFDA then authorized additional JUUL products on August 28, including a JUUL2 menthol product.\n\n\u201cFDA acknowledged that the menthol product carries risks \u2018including youth appeal,\u2019 but concluded that its benefits to adults who smoke outweighed those risks,\u201d Krishnamoorthi wrote. \u201cExactly one month later, FDA announced that it may replace the broader framework governing applications for new tobacco products.\u201d\n\nKrishnamoorthi concluded:\n\n\u201cThe FDA\u2019s job is to protect public health, not make it easier for tobacco companies to evade rigorous scientific review. The agency should crack down on companies selling illegal products, not use their lawbreaking as a rationale for weakening safeguards governing products seeking FDA authorization.\u201d\n\nKrishnamoorthi requested written responses by October 20, 2026, to the following questions:\n\nWhich specific provisions of the 2021 PMTA rule is FDA considering changing or eliminating, and what evidence supports each potential change?\n\nWill FDA commit that any replacement framework will not lower the scientific evidentiary bar manufacturers must meet to demonstrate that marketing their products is appropriate for the protection of public health? If not, why not?\n\nDid FDA discuss potential changes to the 2021 PMTA rule with any tobacco product manufacturer, industry association, or party challenging the 2021 PMTA rule before announcing its review? Please identify each such entity and provide all communications since January 20, 2025, between FDA officials and those entities. Please also provide all communications since January 20, 2025, between FDA officials and Altria, Reynolds American, their subsidiaries or representatives, and any other party challenging the rule concerning the PMTA framework or potential changes to it.\n\nHow does the existence of a widespread illicit market justify changes to the regulatory requirements governing products seeking lawful authorization? What connection has FDA identified between illegal sales and the scientific evidence manufacturers should be required to provide before receiving authorization?\n\nWhat additional enforcement actions will FDA take, in coordination with the Department of Justice and U.S. Customs and Border Protection, to remove unauthorized e-cigarettes from the U.S. market?\n\nThe full letter is available here.", 1, "2026-10-08T11:49:20Z", "2026-10-08T11:50:16Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://krishnamoorthi.house.gov/media/press-releases/krishnamoorthi-demands-answers-fda-move-rewrite-vaping-approval-rules-blasts"], "units": {}, "query_ms": 1.530000939965248, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}